RARE RSI Chart
Last 7 days
-1.4%
Last 30 days
-16.5%
Last 90 days
-6.2%
Trailing 12 Months
-10.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 442.6M | 0 | 0 | 0 |
2023 | 383.9M | 402.9M | 410.2M | 434.2M |
2022 | 331.9M | 334.3M | 343.4M | 363.3M |
2021 | 334.1M | 359.4M | 359.6M | 351.4M |
2020 | 121.9M | 159.4M | 215.1M | 271.0M |
2019 | 59.0M | 70.3M | 84.4M | 103.7M |
2018 | 13.0M | 25.8M | 37.3M | 51.5M |
2017 | 0 | 0 | 331.0K | 2.4M |
2016 | 0 | 322.0K | 370.0K | 282.0K |
2014 | 0 | 331.0K | 0 | 0 |
2013 | 0 | 0 | 0 | 0 |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | crombez eric | sold | -15,455 | 43.66 | -354 | evp and chief medical officer |
Apr 18, 2024 | crombez eric | sold | -6,262 | 44.1 | -142 | evp and chief medical officer |
Apr 16, 2024 | huizenga theodore alan | sold (taxes) | -592 | 42.31 | -14.00 | svp, chief accounting officer |
Mar 11, 2024 | kassberg thomas richard | sold | -574,644 | 49.93 | -11,509 | cbo & evp |
Mar 07, 2024 | fust matthew k | sold | -620,443 | 50.8768 | -12,195 | - |
Mar 01, 2024 | kakkis emil d | acquired | - | - | 41,560 | president & ceo |
Mar 01, 2024 | crombez eric | sold | -66,554 | 53.76 | -1,238 | evp and chief medical officer |
Mar 01, 2024 | harris erik | sold | -256,328 | 53.76 | -4,768 | evp & chief commercial officer |
Mar 01, 2024 | pinion john richard | sold (taxes) | -3,221 | 53.69 | -60.00 | see remarks |
Mar 01, 2024 | huizenga theodore alan | sold (taxes) | -6,496 | 53.69 | -121 | svp, chief accounting officer |
Which funds bought or sold RARE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Candriam S.C.A. | added | 248 | 17,066,000 | 24,166,600 | 0.16% |
May 06, 2024 | SG Americas Securities, LLC | sold off | -100 | -440,000 | - | -% |
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -48.00 | - | -% |
May 06, 2024 | DUALITY ADVISERS, LP | added | 1.54 | -16,195 | 1,866,530 | 0.18% |
May 06, 2024 | Parallel Advisors, LLC | added | 119 | 1,693 | 3,175 | -% |
May 06, 2024 | Savant Capital, LLC | new | - | 338,270 | 338,270 | -% |
May 06, 2024 | TEACHER RETIREMENT SYSTEM OF TEXAS | reduced | -0.79 | -25,000 | 768,000 | -% |
May 03, 2024 | GSA CAPITAL PARTNERS LLP | new | - | 493,000 | 493,000 | 0.04% |
May 03, 2024 | HUNTINGTON NATIONAL BANK | reduced | -2.49 | -1,012 | 20,124 | -% |
May 03, 2024 | Riggs Asset Managment Co. Inc. | new | - | 1,028 | 1,028 | -% |
Unveiling Ultragenyx Pharmaceutical Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ultragenyx Pharmaceutical Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.4B | 6.8B | -7.77 | 6.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.5B | 2.0B | -58.76 | 9.74 | ||||
BMRN | 15.7B | 2.5B | 76.35 | 6.35 | ||||
INCY | 12.2B | 3.8B | 16.38 | 3.24 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 524.1M | -12.77 | 10.17 | ||||
BBIO | 5.2B | 107.9M | -9.51 | 48.09 | ||||
AXSM | 3.7B | 251.0M | -12.33 | 14.56 | ||||
ARWR | 3.1B | 240.7M | -10.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -46.38 | 3.91 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.99 | 4.48 | ||||
NVAX | 645.2M | 983.7M | -1.18 | 0.66 | ||||
CRBP | 424.2M | 881.7K | -12.56 | 481.06 | ||||
INO | 259.6M | 4.9M | -1.92 | 53.35 | ||||
IBIO | 7.1M | 2.1M | -0.26 | 2.14 |
Ultragenyx Pharmaceutical Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -14.6% | 108,833,000 | 127,392,000 | 98,052,000 | 108,309,000 | 100,496,000 | 103,348,000 | 90,703,000 | 89,343,000 | 79,935,000 | 83,389,000 | 81,647,000 | 86,975,000 | 99,395,000 | 91,542,000 | 81,470,000 | 61,709,000 | 36,309,000 | 35,593,000 | 25,800,000 | 24,149,000 | 18,172,000 |
Cost Of Revenue | 45.5% | 17,533,000 | 12,051,000 | 10,987,000 | 9,914,000 | 12,257,000 | 5,319,000 | 8,631,000 | 8,270,000 | 6,100,000 | 3,509,000 | 4,175,000 | 3,136,000 | 5,188,000 | 5,481,000 | 2,348,000 | 1,803,000 | -3,503,000 | 5,107,000 | 2,683,000 | 766,000 | 452,000 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 169,751,000 | 205,964,000 | 187,623,000 | 131,785,000 | 124,764,000 | 156,974,000 | 130,045,000 | 143,833,000 | 136,623,000 | 117,386,000 |
S&GA Expenses | 1.7% | 78,160,000 | 76,833,000 | 74,917,000 | 81,403,000 | 76,646,000 | 72,849,000 | 69,841,000 | 68,137,000 | 67,312,000 | 59,431,000 | 53,883,000 | 53,410,000 | 53,258,000 | 51,042,000 | 42,123,000 | 42,252,000 | 47,516,000 | 41,877,000 | 41,006,000 | 39,812,000 | 38,829,000 |
R&D Expenses | 11.2% | 178,487,000 | 160,557,000 | 157,245,000 | 164,949,000 | 165,698,000 | 170,808,000 | 237,297,000 | 154,529,000 | 143,155,000 | 123,013,000 | 113,417,000 | 113,205,000 | 147,518,000 | 175,080,500 | 87,314,000 | 80,709,000 | 25,000,000 | 83,061,000 | 100,144,000 | 96,045,000 | 78,105,000 |
EBITDA Margin | 1.4% | -1.32 | -1.34 | -1.49 | -1.72 | -1.81 | -1.88 | -1.90 | -1.46 | -1.37 | -1.25 | -0.95 | -0.94 | - | - | - | - | - | - | - | - | - |
Income Taxes | 112.3% | 455,000 | -3,702,000 | 650,000 | 732,000 | 495,000 | -1,451,000 | 6,287,000 | 302,000 | 558,000 | 20,000 | 182,000 | 463,000 | 379,000 | 70,000 | 313,000 | 415,000 | 409,000 | 2,561,000 | 293,000 | 213,000 | 216,000 |
Earnings Before Taxes | -34.2% | -170,229,000 | -126,892,000 | -158,999,000 | -159,096,000 | -163,477,000 | -153,284,000 | -238,819,000 | -157,860,000 | -151,762,000 | -122,438,000 | -72,816,000 | -121,965,000 | -135,762,000 | -23,941,000 | -68,532,000 | 25,730,000 | -118,616,000 | -91,244,000 | -112,701,000 | -98,959,000 | -96,540,000 |
EBT Margin | 0.8% | -1.39 | -1.40 | -1.55 | -1.77 | -1.86 | -1.93 | -1.95 | -1.51 | -1.41 | -1.29 | -0.99 | -0.97 | - | - | - | - | - | - | - | - | - |
Net Income | -38.6% | -170,684,000 | -123,190,000 | -159,649,000 | -159,828,000 | -163,972,000 | -151,833,000 | -245,106,000 | -158,162,000 | -152,320,000 | -122,458,000 | -72,998,000 | -122,428,000 | -136,141,000 | -24,011,000 | -68,845,000 | 25,315,000 | -119,025,000 | -93,805,000 | -112,994,000 | -99,172,000 | -96,756,000 |
Net Income Margin | 0.8% | -1.39 | -1.40 | -1.55 | -1.79 | -1.87 | -1.95 | -1.97 | -1.51 | -1.42 | -1.29 | -0.99 | -0.98 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -126.8% | -193,938,000 | -85,504,000 | -121,569,000 | -130,099,000 | -181,901,000 | -117,312,000 | -121,391,000 | -108,180,000 | -149,705,000 | -70,392,000 | -80,209,000 | -85,427,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -12.3% | 1,307 | 1,491 | 1,238 | 1,311 | 1,383 | 1,545 | 1,618 | 1,321 | 1,384 | 1,522 | 1,485 | 1,512 | 1,598 | 1,760 | 1,268 | 1,314 | 1,233 | 1,135 | 880 | 959 | 1,008 |
Current Assets | -18.6% | 596 | 732 | 599 | 702 | 766 | 884 | 1,013 | 679 | 708 | 857 | 847 | 949 | 1,071 | 1,295 | 872 | 906 | 894 | 851 | 613 | 699 | 787 |
Cash Equivalents | -47.4% | 112 | 214 | 73.00 | 102 | 86.00 | 133 | 392 | 160 | 154 | 308 | 198 | 291 | 384 | 714 | 197 | 336 | 298 | 434 | 123 | 131 | 270 |
Inventory | 5.7% | 36.00 | 34.00 | 32.00 | 28.00 | 27.00 | 27.00 | 22.00 | 21.00 | 18.00 | 16.00 | 15.00 | 15.00 | 12.00 | 13.00 | 14.00 | 11.00 | 11.00 | 12.00 | 14.00 | 14.00 | 11.00 |
Net PPE | -1.9% | 285 | 291 | 297 | 289 | 278 | 260 | 235 | 207 | 177 | 141 | 119 | 105 | 88.00 | 74.00 | 49.00 | 48.00 | 48.00 | 44.00 | 32.00 | 25.00 | 22.00 |
Goodwill | 0% | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 |
Liabilities | -4.0% | 1,167 | 1,216 | 1,206 | 1,182 | 1,163 | 1,193 | 1,150 | 643 | 588 | 600 | 551 | 540 | 543 | 605 | 602 | 618 | 624 | 482 | 153 | 139 | 121 |
Current Liabilities | -12.4% | 246 | 280 | 254 | 244 | 218 | 261 | 227 | 221 | 167 | 181 | 136 | 127 | 127 | 190 | 201 | 220 | 197 | 103 | 90.00 | 75.00 | 67.00 |
Shareholder's Equity | -49.1% | 140 | 275 | 32.00 | 129 | 220 | 352 | 469 | 678 | 796 | 923 | 934 | 972 | 1,055 | 1,154 | 666 | 696 | 609 | 654 | 727 | 820 | 887 |
Retained Earnings | -5.0% | -3,558 | -3,387 | -3,264 | -3,104 | -2,944 | -2,781 | -2,629 | -2,384 | -2,225 | -2,073 | -1,951 | -1,878 | -1,755 | -1,619 | -1,595 | -1,526 | -1,552 | -1,433 | -1,339 | -1,226 | -1,127 |
Additional Paid-In Capital | 1.0% | 3,699 | 3,662 | 3,298 | 3,237 | 3,169 | 3,140 | 3,108 | 3,071 | 3,029 | 2,997 | 2,885 | 2,850 | 2,810 | 2,773 | 2,261 | 2,221 | 2,163 | 2,087 | 2,066 | 2,046 | 2,014 |
Shares Outstanding | 0.9% | 83.00 | 82.00 | 72.00 | 71.00 | 71.00 | 70.00 | 70.00 | 70.00 | 70.00 | 68.00 | 68.00 | 67.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 3,100 | - | - | - | 3,300 | - | - | - | 6,500 | - | - | - | 4,700 | - | - | - | 2,700 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -127.3% | -190 | -83.90 | -117 | -116 | -156 | -90.34 | -95.34 | -77.26 | -117 | -54.34 | -59.65 | -65.36 | -159 | -62.45 | -61.97 | 87.00 | -95.15 | -72.04 | -88.51 | -89.06 | -95.77 |
Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 20.00 | 22.00 | 20.00 |
Cashflow From Investing | 188.2% | 94.00 | -107 | 64.00 | 99.00 | 111 | -171 | -161 | 79.00 | -37.36 | 69.00 | -40.76 | -41.25 | -182 | 98.00 | -95.76 | -86.14 | -95.12 | 67.00 | 79.00 | -58.43 | -101 |
Cashflow From Financing | -100.0% | -0.06 | 331 | 25.00 | 33.00 | -0.72 | 2.00 | 492 | 6.00 | 2.00 | 86.00 | 8.00 | 13.00 | 13.00 | 490 | 19.00 | 36.00 | 56.00 | 315 | 1.00 | 9.00 | 354 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Total revenues | $ 108,833 | $ 100,496 |
Operating expenses: | ||
Cost of sales | 17,533 | 12,257 |
Research and development | 178,487 | 165,698 |
Selling, general and administrative | 78,160 | 76,646 |
Total operating expenses | 274,180 | 254,601 |
Loss from operations | (165,347) | (154,105) |
Interest income | 8,824 | 6,290 |
Change in fair value of equity investments | 3,746 | (334) |
Non-cash interest expense on liabilities for sales of future royalties | (15,847) | (15,636) |
Other income (expense) | (1,605) | 308 |
Loss before income taxes | (170,229) | (163,477) |
Provision for income taxes | (455) | (495) |
Net loss | $ (170,684) | $ (163,972) |
Net loss per share, basic | $ (2.03) | $ (2.33) |
Net loss per share, diluted | $ (2.03) | $ (2.33) |
Shares used in computing net loss per share, Basic | 84,286,292 | 70,368,478 |
Shares used in computing net loss per share, Diluted | 84,286,292 | 70,368,478 |
Product sales | ||
Revenues: | ||
Total revenues | $ 62,489 | $ 44,229 |
Royalty revenue | ||
Revenues: | ||
Total revenues | 46,344 | 4,882 |
Collaboration and license | ||
Revenues: | ||
Total revenues | $ 0 | $ 51,385 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 112,250 | $ 213,584 |
Marketable debt securities | 299,830 | 363,625 |
Accounts receivable, net | 100,253 | 73,390 |
Inventory | 35,907 | 33,969 |
Other assets | 47,727 | 47,616 |
Total current assets | 595,967 | 732,184 |
Property, plant, and equipment, net | 285,111 | 290,566 |
Marketable debt securities | 156,581 | 199,901 |
Intangible assets, net | 165,045 | 166,271 |
Goodwill | 44,406 | 44,406 |
Other assets | 59,970 | 57,685 |
Total assets | 1,307,080 | 1,491,013 |
Current liabilities: | ||
Accounts payable | 40,972 | 42,114 |
Accrued liabilities | 149,133 | 196,486 |
Lease liabilities | 12,781 | 12,595 |
Liabilities for sales of future royalties | 42,689 | 29,242 |
Total current liabilities | 245,575 | 280,437 |
Lease liabilities | 27,979 | 30,574 |
Deferred tax liabilities | 30,058 | 30,058 |
Liabilities for sales of future royalties | 848,725 | 862,325 |
Other liabilities | 14,479 | 12,205 |
Total liabilities | 1,166,816 | 1,215,599 |
Stockholders’ equity: | ||
Preferred stock, par value of $0.001 per share -25,000,000 shares authorized; nil outstanding as of outstanding in 2024 and in 2023 | 0 | 0 |
Common stock, par value of $0.001 per share-250,000,00 shares authorized: outstanding-83,094,037 in 2024 and 82,315,590 in 2023 | 83 | 82 |
Treasury stock, at cost, 63,575 in 2024 and 9,559 in 2023 | (3,332) | (432) |
Deferred compensation obligation | 3,332 | 432 |
Additional paid-in capital | 3,698,957 | 3,662,346 |
Accumulated other comprehensive income (loss) | (431) | 647 |
Accumulated deficit | (3,558,345) | (3,387,661) |
Total stockholders’ equity | 140,264 | 275,414 |
Total liabilities and stockholders’ equity | $ 1,307,080 | $ 1,491,013 |